PD-0325901

PD-0325901 

To Order Contact us: lieven@wlsolutions.be

PD 0325901
GL5463-25	25	EUR 228.1

PD 0325901
GL5463-5	5	EUR 98.4

EZSolution? PD-0325901, Sterile-Filtered
1990-1	each	EUR 326.4

PD-1/PD-L1 Inhibitor 2
B1050-25	each	EUR 679.2

PD-1/PD-L1 Inhibitor 2
B1050-5	each	EUR 242.4

PD-1/PD-L1 Inhibitor 1
B1213-25	each	EUR 679.2

PD-1/PD-L1 inhibitor 2
B6023-25	25 mg	EUR 525.6
Description: PD-1/PD-L1 inhibitor 2 is a PD-1/PD-L1 interaction inhibitor.

PD-1/PD-L1 inhibitor 2
B6023-5	5 mg	EUR 205.2
Description: PD-1/PD-L1 inhibitor 2 is a PD-1/PD-L1 interaction inhibitor.

PD-1/PD-L1 inhibitor 1
B6172-25	25 mg	EUR 543.6
Description: IC50: 0.006-0.10 ?MPD-1/PD-L1 inhibitor 1 is a PD-1/PD-L1 interaction inhibitor.Plenty of studies show that blocking the PD-1/PD-Ll interactions can lead to the restorage and augment of T cell activation in many systems.

PD-1/PD-L1 inhibitor 1
B6172-5	5 mg	EUR 201.6
Description: IC50: 0.006-0.10 ?MPD-1/PD-L1 inhibitor 1 is a PD-1/PD-L1 interaction inhibitor.Plenty of studies show that blocking the PD-1/PD-Ll interactions can lead to the restorage and augment of T cell activation in many systems.

PD-166866
B2223-25	each	EUR 810

PD-166866
B2223-5	each	EUR 248.4

PD-146176
B2313-25	each	EUR 810

PD-146176
B2313-5	each	EUR 248.4

PD-168393
B2352-25	each	EUR 496.8

PD-168393
B2352-5	each	EUR 170.4

PD 169316
B1703-25	each	EUR 652.8

PD 169316
B1703-5	each	EUR 210

PD 151746
B4791-100	100 mg	EUR 714
Description: PD 151746 is a potent and selective inhibitor of calpain with Ki value of 0.26 ?M for ?-Calpain. Calpain is a calcium-dependent, non-lysosomal cysteine protease that expressed in mammals and many other organisms.

PD 151746
B4791-25	25 mg	EUR 338.4
Description: PD 151746 is a potent and selective inhibitor of calpain with Ki value of 0.26 ?M for ?-Calpain. Calpain is a calcium-dependent, non-lysosomal cysteine protease that expressed in mammals and many other organisms.

PD 151746
B4791-5	5 mg	EUR 142.8
Description: PD 151746 is a potent and selective inhibitor of calpain with Ki value of 0.26 ?M for ?-Calpain. Calpain is a calcium-dependent, non-lysosomal cysteine protease that expressed in mammals and many other organisms.

PD 151746
B4791-5.1	10 mM (in 1mL DMSO)	EUR 151.2
Description: PD 151746 is a potent and selective inhibitor of calpain with Ki value of 0.26 ?M for ?-Calpain. Calpain is a calcium-dependent, non-lysosomal cysteine protease that expressed in mammals and many other organisms.

PD 334581
B5727-10	10 mg	EUR 583.2

PD 334581
B5727-50	50 mg	EUR 2220

PD 98059
1666-5	each	EUR 189.6

PD 173074
1675-1	each	EUR 164.4

PD 173074
1675-100	each	Ask for price

PD 150,606
1906-25	each	EUR 444

PD 150,606
1906-5	each	EUR 164.4

PD 173074
27056	10 mg	EUR 125
Description: PD 173074 inhibited the kinase activity of FGFR1 with an IC50 of 25 nM in vitro, while inhibiting Src, the receptors for insulin, epidermal growth factor (EGF) and PDGF, and several serine/threonine kinases with 1000-fold or higher IC50 values. PD 173074 was an ATP-competitive inhibitor of FGFR1, with a Ki of around 40 nM. PD 173074 inhibited autophosphorylation of FGFR1 and VEGFR2 in a dose-dependent manner with IC50s in the range of 1-5 nM and 100-200 nM, respectively.

PD 184161
C4361-10	10 mg	EUR 339.6
Description: IC50: 10-100 nMPD 184161 is a MEK1/2 inhibitor. The intracellular signaling pathway of mitogen-activated protein kinases is involved in the regulation of various cellular functions.

PD 184161
C4361-25	25 mg	EUR 673.2
Description: IC50: 10-100 nMPD 184161 is a MEK1/2 inhibitor. The intracellular signaling pathway of mitogen-activated protein kinases is involved in the regulation of various cellular functions.

PD 184161
C4361-5	5 mg	EUR 217.2
Description: IC50: 10-100 nMPD 184161 is a MEK1/2 inhibitor. The intracellular signaling pathway of mitogen-activated protein kinases is involved in the regulation of various cellular functions.

PD 166326
C3677-1	1 mg	EUR 193.2
Description: IC50: 8 nM for c-abl PD 166326 is a receptor tyrosine kinase inhibitor.Receptor tyrosine kinases are the high-affinity cell surface receptors for many growth factors, cytokines, as well as hormones.

PD 166326
C3677-10	10 mg	EUR 1128
Description: IC50: 8 nM for c-abl PD 166326 is a receptor tyrosine kinase inhibitor.Receptor tyrosine kinases are the high-affinity cell surface receptors for many growth factors, cytokines, as well as hormones.

PD 166326
C3677-5	5 mg	EUR 661.2
Description: IC50: 8 nM for c-abl PD 166326 is a receptor tyrosine kinase inhibitor.Receptor tyrosine kinases are the high-affinity cell surface receptors for many growth factors, cytokines, as well as hormones.

PD 176252
B7122-10	10 mg	EUR 614.4

PD 198306
B7124-1	1 mg	EUR 151.2
Description: IC50: 8 nM for MEK [1]PD 198306 is a potent, selective and non-ATP competitive MAPK/ERK-kinase (MEK) inhibitor. MEK is a kinase enzyme which phosphorylates mitogen-activated protein kinase (MAPK).

PD 198306
B7124-10	10 mg	EUR 634.8
Description: IC50: 8 nM for MEK [1]PD 198306 is a potent, selective and non-ATP competitive MAPK/ERK-kinase (MEK) inhibitor. MEK is a kinase enzyme which phosphorylates mitogen-activated protein kinase (MAPK).

PD 198306
B7124-5	5 mg	EUR 381.6
Description: IC50: 8 nM for MEK [1]PD 198306 is a potent, selective and non-ATP competitive MAPK/ERK-kinase (MEK) inhibitor. MEK is a kinase enzyme which phosphorylates mitogen-activated protein kinase (MAPK).

PD 135158
B7127-10	10 mg	EUR 583.2

PD 135158
B7127-50	50 mg	EUR 2220

PD 158780
B7130-10	10 mg	EUR 278.4

PD 158780
B7130-25	25 mg	EUR 543.6

PD 158780
B7130-5	5 mg	EUR 181.2

PD 118057
B7203-10	10 mg	EUR 400.8

PD 118057
B7203-50	50 mg	EUR 1491.6

PD 146176
B7208-10	10 mg	EUR 180

PD 146176
B7208-25	25 mg	EUR 344.4

PD 146176
B7208-50	50 mg	EUR 567.6

PD 173212
B7424-10	10 mg	EUR 634.8

PD 173212
B7424-5	5 mg	EUR 451.2

PD 173212
B7424-5.1	10 mM (in 1mL DMSO)	EUR 574.8

PD 161570
B7486-10	10 mg	EUR 544.8

PD 161570
B7486-50	50 mg	EUR 2056.8

PD 150606
A4413-25	25 mg	EUR 513.6
Description: PD 150606 is a specific inhibitor of calpain with Ki value of 0.21 ?M and 0.37 ?M for mu- and m- calpains, respectively [1].

PD 150606
A4413-5	5 mg	EUR 172.8
Description: PD 150606 is a specific inhibitor of calpain with Ki value of 0.21 ?M and 0.37 ?M for mu- and m- calpains, respectively [1].

PD 166793
A4438-10	10 mg	EUR 290.4
Description: Broad spectrum MMP inhibitor. Displays high affinity for MMP-2, -3 and -13 (IC50 values are 4, 7 and 8 nM respectively) and exhibits > 750-fold selectivity over MMP-1, -7 and -9. Attenuates left ventricular remodelling and dysfunction in rat model of heart failure.

PD 166793
A4438-25	25 mg	EUR 597.6
Description: Broad spectrum MMP inhibitor. Displays high affinity for MMP-2, -3 and -13 (IC50 values are 4, 7 and 8 nM respectively) and exhibits > 750-fold selectivity over MMP-1, -7 and -9. Attenuates left ventricular remodelling and dysfunction in rat model of heart failure.

PD 166793
A4438-5	5 mg	EUR 224.4
Description: Broad spectrum MMP inhibitor. Displays high affinity for MMP-2, -3 and -13 (IC50 values are 4, 7 and 8 nM respectively) and exhibits > 750-fold selectivity over MMP-1, -7 and -9. Attenuates left ventricular remodelling and dysfunction in rat model of heart failure.

PD 81723
B6705-10	10 mg	EUR 340.8

PD 81723
B6705-50	50 mg	EUR 1245.6

PD 102807
B6821-10	10 mg	EUR 466.8

PD 102807
B6821-50	50 mg	EUR 1771.2

PD 160170
B6972-10	10 mg	EUR 408

PD 180970
A8606-10	10 mg	EUR 517.2
Description: ATP-competitive inhibitor of p210bcr/abl tyrosine kinase; selectively induces apoptosis in chronic myeloid leukemia (CML) K562 cells. Inhibits in vivo tyrosine phosphorylation of Gab2, CrkL and p210bcr/abl (IC50 values are 80, 80 and 170 nM respectively).

PD 169316
A8689-10	10 mg	EUR 195.6
Description: IC50: A potent, selective and cell-permeable suppressor of p38 MAP kinase, with the IC50 value of 89 nM.PD169316, a specific p38 MAPK inhibitor, blocks signal transduction mediated by both TGF-? and Activin A, but not bone morphogenetic protein (BMP) 4.

PD 169316
A8689-5.1	10 mM (in 1mL DMSO)	EUR 268.8
Description: IC50: A potent, selective and cell-permeable suppressor of p38 MAP kinase, with the IC50 value of 89 nM.PD169316, a specific p38 MAPK inhibitor, blocks signal transduction mediated by both TGF-? and Activin A, but not bone morphogenetic protein (BMP) 4.

PD 169316
A8689-50	50 mg	EUR 595.2
Description: IC50: A potent, selective and cell-permeable suppressor of p38 MAP kinase, with the IC50 value of 89 nM.PD169316, a specific p38 MAPK inhibitor, blocks signal transduction mediated by both TGF-? and Activin A, but not bone morphogenetic protein (BMP) 4.

PD 173074
A8253-10	10 mg	EUR 129.6
Description: PD173074 is a poten and selective fibroblast growth factor receptor (FGFR) inhibitor. Fibroblast growth factor-2 is reported to be able to induce proliferation and chemoresistance in Small cell lung cancer (SCLC) cells.

PD 173074
A8253-5.1	10 mM (in 1mL DMSO)	EUR 142.8
Description: PD173074 is a poten and selective fibroblast growth factor receptor (FGFR) inhibitor. Fibroblast growth factor-2 is reported to be able to induce proliferation and chemoresistance in Small cell lung cancer (SCLC) cells.

PD 173074
A8253-50	50 mg	EUR 254.4
Description: PD173074 is a poten and selective fibroblast growth factor receptor (FGFR) inhibitor. Fibroblast growth factor-2 is reported to be able to induce proliferation and chemoresistance in Small cell lung cancer (SCLC) cells.

PD 173074
A8253-S	Evaluation Sample	EUR 97.2
Description: PD173074 is a poten and selective fibroblast growth factor receptor (FGFR) inhibitor. Fibroblast growth factor-2 is reported to be able to induce proliferation and chemoresistance in Small cell lung cancer (SCLC) cells.

PD 145305
C5830-10	10 mg	EUR 513.6
Description: PD 145305 is an inactive analog of PD 150606, a potent and selective calpains inhibitor [1]. Calpain is a class of cytosolic cysteine protease that is activated by elevated intracellular calcium.

PD 145305
C5830-5	5 mg	EUR 315.6
Description: PD 145305 is an inactive analog of PD 150606, a potent and selective calpains inhibitor [1]. Calpain is a class of cytosolic cysteine protease that is activated by elevated intracellular calcium.

PD-ECGF
PR15044	10 ug	EUR 584.4

PD 98,059
GK2140-10MG	10 mg	EUR 206.4

PD 98,059
GK2140-1MG	1 mg	EUR 109.2

PD 98,059
GK2140-50MG	50 mg	EUR 453.6

PD 98,059
GK2140-5MG	5 mg	EUR 164.4

PD 150,606
GL2543-25MG	25 mg	EUR 495.6

PD 150,606
GL2543-5MG	5 mg	EUR 184.8

PD-ECGF
GT15181	100 ug	EUR 631.2

PD 0332991
E1KS1116	5mg	EUR 812.4

PD-166866
HY-101296	10mM/1mL	EUR 165.6

PD-159020
HY-101598	1mg	EUR 1350

PD 123319
HY-10259	5mg	EUR 218.4

PD 169316
HY-10578	10mM/1mL	EUR 306

PD 90780
HY-110166	5mg	EUR 391.2

PD 407824
HY-18961	100mg	EUR 1850.4

PD 151746
HY-19749	50mg	EUR 589.2

PD 117519
HY-100032	5mg	EUR 142.8

PD 150,606
GL2543-25	25	EUR 393.3

PD 150,606
GL2543-5	5	EUR 127.7

PD 98,059
GK2140-1	1	EUR 63

PD 98,059
GK2140-10	10	EUR 151.4

PD 98,059
GK2140-5	5	EUR 98.4

PD 98,059
GK2140-50	50	EUR 369.6

PD-173955
GW0583-1	1	EUR 311.9

PD-173955
GW0583-10	10	EUR 748.1

PD-173955
GW0583-5	5	EUR 492

PD-1:PD-L1 Homogeneous Assay Kit
72014	384 rxns.	EUR 1070
Description: The PD-1:PD-L1 Homogeneous Assay Kit is designed to measure the_x000D_inhibition of PD-1 binding to PD-L1. With this kit, only three simple steps on a microtiter_x000D_plate are required. First, a sample containing PD-1 and an inhibitor of choice is incubated with_x000D_the biotinylated PD-L1 for 60 minutes. Next, acceptor beads are added, then donor beads,_x000D_followed by reading the Alpha-counts.

PD-1:PD-L2 Homogeneous Assay Kit
72015	384 rxns.	EUR 1070
Description: The PD-1:PD-L2 Homogeneous Assay Kit is designed to measure the_x000D_inhibition of PD-1 binding to PD-L2. With this kit, only three simple steps on a microtiter_x000D_plate are required. First, a sample containing PD-1 and an inhibitor of choice is incubated with_x000D_the biotinylated PD-L2 for 60 minutes. Next, acceptor beads are added, then donor beads,_x000D_followed by reading the Alpha-counts.

PD-1:PD-L1 TR-FRET Assay
72032	96 rxns.	EUR 745
Description: The PD-1:PD-L1 TR-FRET Assay is designed to measure the inhibition of PD-1 binding to PD-L1 in a homogeneous 96 reaction format. This FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. The assay procedure is straightforward and simple; a sample containing europium-labeled (Eu) PD-1, dye-labeled acceptor, biotin-labeled PD-L1, and an inhibitor is incubated for two hours. Then, the fluorescence intensity is measured using a fluorescence reader.

PD-1:PD-L1 TR-FRET Assay
72038	384 rxns.	EUR 845
Description: The PD-1:PD-L1 TR-FRET Assay is designed to measure the inhibition of PD-1 binding to PD-L1 in a homogeneous 384 reaction format. This FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. The assay procedure is straightforward and simple; a sample containing europium-labeled (Eu) PD-1, dye-labeled acceptor, biotin-labeled PD-L1, and an inhibitor is incubated for two hours. Then, the fluorescence intensity is measured using a fluorescence reader.

PD-1:PD-L1/PD-L2 Cell-Based Inhibitor Screening Assay Kit
60800	96 rxns.	EUR 1070
Description: The PD-1/PD-L1 Inhibitor Screening Cell-Based Assay is a bioluminescent cell-based assay that can be used to screen and profile inhibitors of PD-1:PD-L1 or PD-1:PD-L2 interaction. The assay consists of two main components:_x000D_ • PD-1 Effector cells (PD-1/NFAT reporter-Jurkat cells): Reporter Jurkat T cells expressing firefly luciferase gene under the control of NFAT response elements and also constitutively expressing human PD-1. These cryopreserved cells are provided in a thaw-and-use format that does not require cell propagation._x000D_ • _x000D_Expression vectors for TCR activator, human PD-L1, and human PD-L2: Transfection-ready vectors are used to transfect cells to create the target cells that overexpress PD-L1 or PD-L2 and an engineered cell surface T cell receptor (TCR) activator._x000D_

PD-1:PD-L2 TR-FRET Assay Kit
72012	384 rxns.	EUR 1070
Description: The PD-1:PD-L2 TR-FRET Assay Kit is designed to measure the inhibition of PD-1 binding to_x000D_PD-L2 in a homogeneous 384 reaction format. Cell signaling through the PD-1 receptor upon_x000D_binding the PD-L2 ligand attenuates immune responses and is exploited by both tumors and_x000D_viruses. This FRET-based assay requires no time-consuming washing steps, making it_x000D_especially suitable for high throughput screening applications. The assay procedure is_x000D_straightforward and simple; a sample containing europium-labeled (Eu) PD-1, dye-labeled_x000D_acceptor, biotin-labeled PD-L2, and an inhibitor is incubated for two hours. Then, the_x000D_fluorescence intensity is measured using a fluorescence reader.

PD-1[Biotinylated]:PD-L1 Homogeneous Assay Kit
72028	384 rxns.	EUR 1070
Description: The PD-1[Biotinylated]:PD-L1 Homogeneous Assay Kit is designed to measure_x000D_the inhibition of PD-1 binding to PD-L1. The PD-1[Biotinylated]:PD-L1 Homogeneous Assay Kit_x000D_comes in a convenient AlphaLISA® format with purified biotinylated PD-1, FLAG-tagged PD-L1,_x000D_and assay buffer to perform a total of 384 reactions. With this kit, only three simple steps on a_x000D_microtiter plate are required. First, a sample containing biotinylated PD-1 and an inhibitor of_x000D_choice is incubated with the FLAG-tagged PD-L1 for 60 minutes. Next, acceptor beads are_x000D_added, then donor beads, followed by reading the Alpha-counts.

Ribosome-inactivating protein PD-L1 / PD-L2 Antibody
20-abx319445	EUR 493.20 EUR 2214.00 EUR 718.80 EUR 218.40 EUR 360.00	100 ug 1 mg 200 ug 20 ug 50 ug

Ribosome-inactivating protein PD-L1/PD-L2 Antibody
1-CSB-PA306294LA01PJJ	EUR 380.40 EUR 402.00	100ug 50ug
Description: A polyclonal antibody against Ribosome-inactivating protein PD-L1/PD-L2. Recognizes Ribosome-inactivating protein PD-L1/PD-L2 from Phytolacca dioica. This antibody is Unconjugated. Tested in the following application: ELISA

PD-L1 Protein
20-abx261703	EUR 4101.60 EUR 393.60 EUR 276.00	1 mg 20 ug 5 ug

PD-L1 Protein
20-abx263458	EUR 1930.80 EUR 393.60 EUR 276.00	100 ug 10 ug 2 µg

PD-ECGF Antibody
abx236264-100ug	100 ug	EUR 661.2

PD-166285 dihydrochloride
B2094-25	each	EUR 757.2

PD-166285 dihydrochloride
B2094-5	each	EUR 235.2

PD-L1 (CD274)
100443-1	100 µg	EUR 320
Description: Human secreted Programmed Cell Death 1 Ligand 1 (PD-L1) protein, also known as CD274, PDCD1L1, and B7 homolog 1 (B7-H1), GenBank Accession No. NM_014143, a.a. 19-239, expressed in an E. coli expression system. MW = 25 kDa.

PD-L1 (CD274)
100443-2	1 mg	EUR 2720
Description: Human secreted Programmed Cell Death 1 Ligand 1 (PD-L1) protein, also known as CD274, PDCD1L1, and B7 homolog 1 (B7-H1), GenBank Accession No. NM_014143, a.a. 19-239, expressed in an E. coli expression system. MW = 25 kDa.

PD 153035 Hydrochloride
1656-2	each	EUR 189.6

PD-1 Antibody
24505-100ul	100ul	EUR 468

PD-1 Antibody
24506-100ul	100ul	EUR 468

EZSolution? PD 98059
1783-5	each	EUR 189.6

PD 98059, >99%
BC064-010	10mg	EUR 278.4

PD 98059, >99%
BC064-025	25mg	EUR 360

PD 98059, >99%
BC064-050	50mg	EUR 537.6

PD 144418 oxalate
B7125-10	10 mg	EUR 408

PD 144418 oxalate
B7125-50	50 mg	EUR 1531.2

PD 168568 dihydrochloride
B7420-10	10 mg	EUR 369.6

PD 168568 dihydrochloride
B7420-50	50 mg	EUR 1363.2

PD 0332991 (Palbociclib)
B7798-25	25 mg	EUR 184.8
Description: PD-0332991 is selective and oral inhibitor of cyclin-dependent kinase 4/6 with IC50 values of 11nM and 16nM, respectively for CDK4 and CDK6 [1].PD-0332991 is a highly specific inhibitor of CDK4/6.

PD 0332991 (Palbociclib)
B7798-5	5 mg	EUR 129.6
Description: PD-0332991 is selective and oral inhibitor of cyclin-dependent kinase 4/6 with IC50 values of 11nM and 16nM, respectively for CDK4 and CDK6 [1].PD-0332991 is a highly specific inhibitor of CDK4/6.

PD 0332991 (Palbociclib)
B7798-S	Evaluation Sample	EUR 97.2
Description: PD-0332991 is selective and oral inhibitor of cyclin-dependent kinase 4/6 with IC50 values of 11nM and 16nM, respectively for CDK4 and CDK6 [1].PD-0332991 is a highly specific inhibitor of CDK4/6.

PD-L1 Antibody
4059-002mg	0.02 mg	EUR 206.18
Description: PD-L1 plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/CD279, PD-L1 modulates the activation threshold of T-cells and limits T-cell effector response (1). The PDCD1/CD279-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival (2,3). Through a yet unknown activating receptor, it may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (4).

PD-L1 Antibody
4059-01mg	0.1 mg	EUR 523.7
Description: PD-L1 plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/CD279, PD-L1 modulates the activation threshold of T-cells and limits T-cell effector response (1). The PDCD1/CD279-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival (2,3). Through a yet unknown activating receptor, it may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (4).

PD-L1 Peptide
4059P	0.05 mg	EUR 197.7
Description: (IN) PD-L1 peptide

PD-L2 Antibody
4063-002mg	0.02 mg	EUR 206.18
Description: PD-L2 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by co gnate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2, both of which are thought act as a negative regulator of T cell activation. However, it has been suggested that PD-L2 can act to stimulate an immunogenic response through and alternative receptor from PD-1.

PD-L2 Antibody
4063-01mg	0.1 mg	EUR 523.7
Description: PD-L2 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by co gnate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2, both of which are thought act as a negative regulator of T cell activation. However, it has been suggested that PD-L2 can act to stimulate an immunogenic response through and alternative receptor from PD-1.

PD-L2 Peptide
4063P	0.05 mg	EUR 197.7
Description: (IN) PD-L2 peptide

PD-1 Antibody
4065-002mg	0.02 mg	EUR 206.18
Description: PD-1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antig en-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD1-null mice who exhibit hyperactivated immune systems and autoimmune diseases.

PD-1 Antibody
4065-01mg	0.1 mg	EUR 523.7
Description: PD-1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antig en-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD1-null mice who exhibit hyperactivated immune systems and autoimmune diseases.

PD-1 Peptide
4065P	0.05 mg	EUR 197.7
Description: (CT) PD-1 peptide

PD-1 Antibody
4067-002mg	0.02 mg	EUR 206.18
Description: PD-1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antig en-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD1-null mice who exhibit hyperactivated immune systems and autoimmune diseases.

PD-1 Antibody
4067-01mg	0.1 mg	EUR 523.7
Description: PD-1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antig en-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD1-null mice who exhibit hyperactivated immune systems and autoimmune diseases.

PD-1 Peptide
4067P	0.05 mg	EUR 197.7
Description: (IN) PD-1 peptide

PD 123319 ditrifluoroacetate
A3704-10	10 mg	EUR 250.8
Description: Description:IC50 Value: 1.2 ±0.4 mM (Inhibition of adenylyl cyclase elicited by 0.1 microM Ang II) [2]PD 123319 ditrifluoroacetate is a potent, selective, non-peptide angiotensin AT2 receptor antagonist.

PD 123319 ditrifluoroacetate
A3704-25	25 mg	EUR 489.6
Description: Description:IC50 Value: 1.2 ±0.4 mM (Inhibition of adenylyl cyclase elicited by 0.1 microM Ang II) [2]PD 123319 ditrifluoroacetate is a potent, selective, non-peptide angiotensin AT2 receptor antagonist.

PD 123319 ditrifluoroacetate
A3704-5	5 mg	EUR 205.2
Description: Description:IC50 Value: 1.2 ±0.4 mM (Inhibition of adenylyl cyclase elicited by 0.1 microM Ang II) [2]PD 123319 ditrifluoroacetate is a potent, selective, non-peptide angiotensin AT2 receptor antagonist.

PD 123319 ditrifluoroacetate
A3704-50	50 mg	EUR 787.2
Description: Description:IC50 Value: 1.2 ±0.4 mM (Inhibition of adenylyl cyclase elicited by 0.1 microM Ang II) [2]PD 123319 ditrifluoroacetate is a potent, selective, non-peptide angiotensin AT2 receptor antagonist.

PD 168077 maleate
B6578-10	10 mg	EUR 362.4

PD 168077 maleate
B6578-50	50 mg	EUR 1315.2

PD-L1 Antibody
49251-100ul	100ul	EUR 399.6

PD-L1 Antibody
49251-50ul	50ul	EUR 286.8

PD-L1 Peptide
46-156P	0.1 mg	EUR 405.6
Description: CD274 / PD-L1 Peptide

PD-123319 ditrifluoroacetate
9640-25	each	EUR 757.2

PD-123319 ditrifluoroacetate
9640-5	each	EUR 235.2

PD-0332991 isethionate
9480-25	each	EUR 652.8

PD-0332991 isethionate
9480-5	each	EUR 210

Anti-PD-L1
DB-241-0.1	100 μl	EUR 469.2
Description: rabbit monospecific clonal antibodies for ihc-p application; concentrated

Anti-PD-L1
DB-241-0.2	200 μl	EUR 675.6
Description: rabbit monospecific clonal antibodies for ihc-p application; concentrated

PD-0325901